Business Context and Reporting Period
Company: ILLUMINA, INC. (ILMN)
Filing Type: Form 8-K (Current Report)
Date of Report: January 30, 2026
Event: Completion of the acquisition of Standard BioTools Inc.'s aptamer-based and functional proteomics business (the "Business").
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial results. Key financial terms include:
- Purchase Price: $350,000,000 in cash (subject to customary adjustments).
- Contingent Consideration: Up to $75,000,000 in potential milestone payments based on revenue from certain products and services.
- Additional Obligations: Royalty streams payable to Standard BioTools.
- Assets Acquired: All issued and outstanding shares of SomaLogic, Inc., all LLC interests in Sengenics Corporation LLC, and all ordinary shares of Sengenics Corporation Pte Ltd.
- Excluded Assets: Standard BioTools' mass cytometry and microfluidics businesses.
Note: The filing text does not provide clear values for Illumina's overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the successful closing of the Transaction previously announced on June 23, 2025. Illumina has expanded its portfolio to include KREX, Single SOMAmer, and translational and diagnostic assays. The transaction was completed on January 30, 2026, finalizing the transfer of the specified Group Companies to Illumina.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued a press release confirming the completion of the transaction. The acquisition is intended to integrate the Business's technology and products into Illumina's existing operations.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Success of integrating the acquired Business into existing operations.
- Ability to sell products and further develop the acquired technology.
- Challenges in manufacturing robust instrumentation and consumables.
- Reliance on third-party suppliers for critical components.
- Customer uptake and satisfaction with new products.
- Competitive dynamics in the proteomics market.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments are applied.
- Review the specific terms of the royalty streams and the revenue thresholds required to trigger the $75,000,000 in milestone payments.
- Assess the integration plan for SomaLogic and Sengenics technologies into Illumina's current product lines.
- Monitor future filings (10-K/10-Q) for the impact of this acquisition on consolidated revenue and operating expenses.
- Confirm the status of any regulatory approvals or conditions precedent that may have been outstanding prior to the January 30, 2026 closing.